Shares of GSK plc traded lower during the early session in London on Monday, March 2, 2026, mirroring a broader decline in the UK's benchmark index. The pharmaceutical giant's stock was down approximately 1.1%, reaching 2,177 pence by 0823 GMT after moving between 2,172 and 2,194 pence.
The pullback occurred against a backdrop of heightened market volatility, driven primarily by a sharp increase in crude oil prices. Fresh hostilities in the Middle East disrupted shipping traffic near the critical Strait of Hormuz, prompting a flight to safer assets and renewing worries about persistent inflation. The FTSE 100 index was down roughly 0.7%, with sector peer AstraZeneca also trading in negative territory.
"Financial markets are clearly registering the severity of the ongoing conflict," noted Priyanka Sachdeva, a senior market analyst at Phillip Nova. "However, the current price action suggests investors are treating this primarily as a geopolitical shock for now, rather than a catalyst for a broader systemic crisis."
Share Buyback Program Advances
Amid the market turbulence, GSK provided an update on its ongoing share repurchase initiative. The company disclosed that on February 27, it repurchased 430,000 of its ordinary shares through BNP Paribas. The transaction was executed at an average price of 2,179.36 pence per share, weighted by volume.
This latest purchase is part of a larger program that began on February 17. To date, GSK has bought back 4,136,000 shares. These repurchased shares are held in treasury, bringing the company's total treasury holdings to 244,027,094 shares. This represents approximately 5.99% of GSK's total voting rights. Companies often hold repurchased shares in treasury rather than canceling them, a move that can reduce the number of shares effectively outstanding and potentially boost earnings per share over time.
Market Context and Risks
The immediate trading environment is likely to be dominated by macroeconomic headlines rather than individual corporate stories. Investors are awaiting key U.S. economic data scheduled for release this week, including manufacturing surveys and labor market reports. Trader attention remains split between energy prices and the trajectory of interest rates.
A significant risk for GSK and the wider equity market is the potential for sustained high energy costs. A prolonged period of elevated oil prices could harden inflation expectations, leading central banks to maintain restrictive monetary policies. This scenario could pressure equity valuations across the board. Even defensive sectors like healthcare are not immune during periods of acute market stress, as investors may sell liquid holdings to raise cash regardless of underlying earnings stability.
Upcoming Regulatory Catalyst
Looking beyond the near-term market noise, GSK's next significant company-specific event is regulatory. The U.S. Food and Drug Administration has set a target date of March 24, 2026, to decide on the marketing application for linerixibat. The drug is intended to treat cholestatic pruritus in patients with primary biliary cholangitis, a chronic liver disease.
"The FDA's acceptance of this filing marks an important milestone for this potential treatment," said Kaivan Khavandi, a senior vice president in GSK's research and development division, when the regulatory review commenced. Linerixibat is not currently approved for use in any market, making the upcoming FDA decision a pivotal event for the company's pipeline.
As trading continues, investors will monitor the interplay between broader risk sentiment driven by geopolitics and oil, the steady execution of GSK's capital return program, and the approaching regulatory deadline that could influence the stock's longer-term trajectory.
